Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LPM3770164 in Tardive Dyskinesia
NCT06731868Phase 2Recruiting
- Sponsor
- Luye Pharma Group
- Start
- Jan 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LPM3770164 in tardive dyskinesia (TD), sponsored by Luye Pharma Group. Primary endpoints: Treatment-Emergent Adverse Events at 8 weeks and Change in Abnormal Involuntary Movement Scale Dyskinesia Total Score at 8 weeks. Started Jan 2025; status: recruiting.
02
Drugs
LPM3770164
03
Conditions
tardive dyskinesia (TD)
Beyond the preview
Go deeper on NCT06731868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06731868.